Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Breast Neoplasms 184HER2-positive Breast Cancer 18Neoplasms 13Neoplasm Metastasis 11Prostatic Neoplasms 7Ovarian Neoplasms 7Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Inflammatory Breast Neoplasms 5Colonic Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Multiple Myeloma 4Hematologic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Solid Tumor 3Rectal Neoplasms 3Pathologic Complete Response 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3HER2-positive Early Breast Cancer 3Esophageal Neoplasms 3Breast Neoplasms, Male 3Biliary Tract Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Salivary Gland Neoplasms 2Locally Advanced Breast Cancer 2

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4spartalizumab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3Midazolam 3Itraconazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumor × pertuzumab × Clear all
NCT02593708 2017-11-17

Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+

University of California, San Francisco

Phase 1 Terminated
6 enrolled
Other solid neoplasm

Solid Tumor

NCT02490475 2017-05-17

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
19 enrolled 25 charts
Other solid neoplasm

Solid Tumor

NCT02494596 2015-11-10

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
19 enrolled 16 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡